Efforts to increase domestic and foreign investment in Sri Lanka’s pharmaceuticals industry is set to boost output, Oxford Business Group (OBG) said in its recent Sri Lanka economic update.
OBG said latest measures will also broaden the sector’s product range, bringing the country closer to the government’s goal of self-sufficiency in medical production.
In early January the State Pharmaceuticals Manufacturing Corporation (SPMC) announced it was joining with Malaysian investment firm Pharma Zone to develop a dedicated industrial centre for the manufacture of pharmaceuticals.
Pharma Zone, a partnership of the Sultan of Johor and Malaysian property development company Equine Capital, will provide 10 million dollars for the construction of infrastructure necessary for pharmaceuticals production.
To attract investment to the 50-ha site, to be located in the Kalutara district, south of the commercial capital, Colombo, the state has offered a 15-year buyback guarantee to purchase pharmaceuticals from manufacturers operating within the zone at 20 percent above unit cost.
Lohitha Samarawickrema, the president of the National Chamber of Pharmaceutical Manufacturers of Sri Lanka (NCPM), said that at least 17 local producers had signed MOUs with the SPMC to establish manufacturing facilities within the zone, with each committing a minimum of 4 million dollars to secure blocks of 2-4 ha for development.
Manufacturing zones key to self-sufficiency strategy
The initial facilities in the zone are scheduled to come into operation in the first half of 2019, and by 2020 total output is expected to meet around 60 percent of domestic requirements, according to the NCPM.
At present, locally manufactured pharmaceuticals account for just 12 percent of the market.
The increase in local production is expected to significantly reduce the sector’s annual import bill, which currently stands at 400 million to 500 million dollars.
The strategy is also being supported by other investments in the sector.
In early February the government signed an agreement to construct a new 1.4 billion rupees ($9m) facility for the production of cancer-treating drugs using nanotechnology.
The plant, to be located in Payagala’s Malegoda district, is a joint venture between the SPMC and two Indian pharma companies, and aims to bring down the cost of cancer drugs, most of which are currently imported at prices of around 150,000 rupees ($960) per item.
While the goal of producing 100 percent of pharmaceuticals locally is a long-term one, with industry officials estimating that it will be achieved by the end of the next decade, Sanjaya Jayaratne, chairman of Navesta Pharmaceuticals, said recent developments showed the sector is moving in the right direction.
Technological improvement needed to meet expansion targets
OBG economic update, however, said although making progress, Sri Lanka still faces a series of challenges if it is to meet its goals for the pharmaceuticals sector.
One such challenge relates to sourcing raw packing materials such as sterile and industry-compliant packaging, which are not available locally and must be imported.
Another relates to the provision of equipment and technology for medical production. At present, the necessary technological capacity for large-scale pharmaceuticals expansion is lacking, and although the local industry will benefit from development in this area, it will initially rely on imports